Your support fuels our research to #EndALS! Donate Now



Highly related to the Parkinson’s disease drug pramipexole (Mirapex), the neuroprotectant dexpramipexole (Empower) may slow the progression of ALS by keeping the power on in deteriorating motor nerves. Dexpramipexole is thought to maintain mitochondrial function in people with ALS by increasing the efficiency of ATP production.


Type: Small Molecule
Stage: Phase III
Status: Completed
Sponsor: Biogen Idec

TDI Says:

A Phase III clinical trial on dexpramipexole was completed in 2012. Results and analysis reported by clinical trial sponsor Biogen Idec showed no statistically significant slowing of disease progression in people with ALS treated with dexpramipexole compared to those treated with placebo.

Learn More

  • ALS clinical trials, powering forward

    Biogen Idec's Doug Kerr MD PhD talks dexpramipexole - the lessons learned and the development of future ALS medicines going forward.

  • ALS/MND 2012: Trials and tribulations

    Emerging ALS medicines show promise. But key challenges remain to bring them forward to the ALS clinic according to new studies unveiled at ALS MND Chicago.

  • ALS, off the beaten track

    Emerging ALS mitochondrial-targeted medicines are gathering steam. But, these medicines may need to do a lot more than boost energy production to stop the disease.

Published Results

Comment on this Topic

(All comments are moderated before they appear here.)